Non-viral based gene therapies represent one possible tissue engineering-based approach to improve bone regeneration. Unique target proteins for gene therapy are transcription factors. These are nuclear based proteins that can not feasibly be applied as mature proteins. Therefore, protein based therapies can not be utilized. Gene therapy is the only option. However, it remains unclear which tra...

Anticipating new spectroscopic studies of quasar companions, we calculate expected emission line spectra for the companion galaxies. Under the assumption of isotropic photoionizing radiation, we predict equivalent widths for Hα, Hβ, [O iii] λ5007, [O ii] λ3727, [Ne iii] λ3869, and Mg ii λ2798 lines. We consider 6 quasars, two of which (PKS 213514 and PKS 2349-014) have very close companions wit...

We have extended the Tiny Tim HST point-spread function simulator so that it can now generate PSFs for the Wide Field Camera 3. This ISR describes the changes and sources of information used and shows some comparisons between modeled PSFs and those observed with the CASTLE stimulus during thermal vacuum testing. A web interface to the same simulation software is also available. Introduction Tin...

1 9-Deformyl derivatives of desmycosin 1 16-membered macrolide antibiotics lacking an aldehyde group with strong activity against Gram-positive aerobes, anaerobes and mycoplasmas.3) Among the derivatives, 19-deformyl-4'deoxydesmycosin (TMC-016) has been shown to be 4to 7-fold more potent than erythromycin against Gram-positive bacterial infections in experimental animals. 3) In this study we in...

When analysing the behavior of complex networked systems, it is often the case that some components within that network are only known to the extent that they belong to one of a set of possible ”implementations” – e.g., versions of a specific protocol, class of schedulers, etc. In this report we augment the specification language considered in BUCSTR-2004-021, BUCS-TR-2005-014, BUCS-TR-2005-015...

Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000's. The path to the commercialization of oncology drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development. The pace at which phar...